WWW.EXFILE.COM -- BOSTON SCIENTIFIC -- FORM 8-K -- 15747
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 12, 2008
BOSTON SCIENTIFIC
CORPORATION
(Exact
name of registrant as specified in charter)
DELAWARE
|
1-11083
|
04-2695240
|
(State or
other jurisdiction of incorporation)
|
(Commission file
number)
|
(IRS employer
identification no.)
|
One Boston Scientific Place, Natick,
Massachusetts
|
01760-1537
|
(Address of
principal executive offices)
|
(Zip
code)
|
Registrant’s telephone number, including area code: (508) 650-8000
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the fling obligation of the registrant under any of the following
provisions:
[
] Written communication pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02.
|
DEPARTURE
OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF
CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.
|
Our
Compensation Committee has approved retention awards for certain members of our
Executive Committee in order to address concerns about retaining members of our
senior management team during a challenging but critical period for the
Company. The individuals were permitted to select the form of the
award among a combination of stock options, deferred stock units (DSUs) and
cash. The awards were issued on February 12, 2008 once the selections
were processed and reviewed by the Compensation Committee. The stock
options and DSUs are subject to the standard terms and conditions under our 2003
Long-Term Incentive Plan but will vest ratably over two years, and the cash will
be paid ratably over two years. The executives listed below were
granted the following retention awards as of February 12, 2008:
Name
|
Title
|
|
Stock Options
|
|
|
DSUs
|
|
|
Cash
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brian
Burns
|
Senior
Vice President, Quality
|
|
|
n/a |
|
|
|
13,626 |
|
|
$ |
170,900 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fredericus
Colen
|
Executive
Vice President, Operations and Technology, CRM
|
|
|
76,705 |
|
|
|
26,957 |
|
|
|
n/a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paul
Donovan
|
Senior
Vice President, Corporate Communications
|
|
|
n/a |
|
|
|
12,827 |
|
|
$ |
160,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James
Gilbert
|
Executive
Vice President, Strategy and Business Development
|
|
|
153,409 |
|
|
|
n/a |
|
|
|
n/a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
William
Kucheman
|
Senior
Vice President and Group President, Interventional
Cardiology
|
|
|
n/a |
|
|
|
7,987 |
|
|
$ |
100,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
William
McConnell
|
Senior
Vice President, Sales, Marketing and Administration, CRM
|
|
|
n/a |
|
|
|
16,573 |
|
|
$ |
207,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David
McFaul
|
Senior
Vice President, International
|
|
|
136,364 |
|
|
|
n/a |
|
|
|
n/a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stephen
Moreci
|
Senior
Vice President, Group President, Endosurgery
|
|
|
70,750 |
|
|
|
n/a |
|
|
|
n/a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kenneth
Pucel
|
Executive
Vice President, Operations
|
|
|
n/a |
|
|
|
16,773 |
|
|
$ |
210,300 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lucia
Quinn
|
Executive
Vice President, Human Resources
|
|
|
61,364 |
|
|
|
21,565 |
|
|
|
n/a |
|
SIGNATURE
Pursuant
to the requirements of the Securities and Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
BOSTON
SCIENTIFIC CORPORATION |
|
|
|
|
|
Date:
February 15, 2008
|
By:
|
/s/
Lawrence J. Knopf |
|
|
|
Lawrence
J. Knopf |
|
|
|
Senior
Vice President and Deputy General Counsel |
|
|
|
|
|